Who are we?
Our story
Founded in March 2020 by two pharmacists,
Ethyx Pharmaceuticals is a private company with its headquarters in Montrouge (92) and its pharmaceutical office in Lyon (69). Our company benefits from a solid experience in acquisitions and integrations of mature medicines.
We are currently present in six different therapeutic areas: Metabolism, Cardiology, Rheumatology, Dermatology, Pneumology and Neurology.
March 2020
Creation of the Ethyx Pharmaceuticals company
October 2020
Acquisition of Tensionorme®
(Lab. Du Tensionorme)
December 2020
Acquisition of Toco500®, Veinamitol®/Rheoflux® and Art50®
(Wockhardt France)
February 2021
Acquisition of Isocard®, Timacor® , Epitopic® and Pulmofluide®
(Laboratoire Gerda)
2022
Acquisition of Lescol®, Mosegor® and Sandomigran® (Novartis)
2023
Next acquisitions planned in 2023
Our presence
around the world
Ethyx Pharmaceuticals medicines are present in 48 countries, in Europe, in Africa, in Middle-East and in Asia.
Executive committee
-
-
CEO
© Nathalie Oundjian
Sébastien Clerc, President and Founder, Pharmacist
Experts
© Nathalie Oundjian
Bérenger Reynaud-Cleyet, Chief Operating Officer
& Co-founder, Pharmacist
© Nathalie Oundjian
Julie Duvernois, Responsible Pharmacist
© Nathalie Oundjian
Guillaume Demaille, Director of Industrial and Logistics Operations
© Nathalie Oundjian
Guillaume Bellon, Chief Financial Officer
Our skills
With our transversal experience, our team has all the skills needed to ensure a smooth and simple integration of mature products into Ethyx’ portfolio.
Our key word is continuity. Uninterrupted treatment is essential for patients and this requirement is our priority in the long term.
We rely on a network of complementary external skills that allow us to make acquisitions with complete peace of mind. The rapid growth of our portfolio is proof of this.
Our strategy
Our core business is the acquisition and integration of mature medicines to which we give a second breath. Our mission is to provide access to quality treatments for the greatest number of people worldwide.
Our ambition is to combine our already strong acquisition/integration activity with R&D projects, particularly in the field of pediatric treatments.
Our strategy
Our core business is the acquisition and integration of mature medicines to which we give a second breath. Our mission is to provide access to quality treatments for the greatest number of people worldwide.
Our ambition is to combine our already strong acquisition/integration activity with R&D projects, particularly in the field of pediatric treatments.